No new clinical data released today. Monitor the ENA Symposium abstract release on November 4, 2026, and the poster presentation on November 20, 2026, for potential catalysts. The pending Cohort 3 and 4 efficacy data remain the key read-through for the program's viability.
Price Chart
Executive Summary
Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program for neuroendocrine tumors (NETs) has been accepted for presentation at the ENA Symposium in November 2026. The abstract will cover safety and efficacy results from Cohorts 1-3, with additional data from later cohorts still pending. This is a routine clinical update with no new data released today, and the stock impact is likely minimal.
Key Facts
- Updated data on [212Pb]VMT-α-NET accepted for poster presentation at ENA Symposium (Nov 18-20, 2026, Barcelona)
- Abstract covers safety and efficacy results for Cohorts 1-3 in advanced SSTR2+ NETs
- Abstract number 334, session date November 20, 2026
- Data cut-off for prior ASCO presentation was April 17, 2026; initial efficacy from Cohorts 1 and half of Cohort 2 already presented at ASCO 2026
- Initial efficacy data for remaining Cohort 2 patients and Cohorts 3 and 4 are still pending
- Company plans to submit additional data for future conferences in 2026 and 2027
Financial Impact
No financial data disclosed; clinical update only
Risk Factors
- Clinical trial results may not support further development
- Competition from other radiopharmaceutical therapies (e.g., Lutathera)
- Regulatory and manufacturing risks for alpha-emitting isotope supply
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360200 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.28 | awaiting T+20 | — | $1.25 (−44.96%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.25 (−53.69%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.25 (−54.53%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.25 (−57.02%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.25 (−55.34%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.25 (−58.03%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.25 (−59.78%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.25 (−59.78%) |
Aug 10, 2026 10w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.25 (−60.53%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.25 (−58.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers